
Samira Jm Jean-louis
Examiner (ID: 14140)
| Most Active Art Unit | 1627 |
| Art Unit(s) | 1627, 1617, 1642, 1609 |
| Total Applications | 1383 |
| Issued Applications | 704 |
| Pending Applications | 44 |
| Abandoned Applications | 639 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19065615
[patent_doc_number] => 20240100041
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/531086
[patent_app_country] => US
[patent_app_date] => 2023-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15156
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18531086
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/531086 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES | Dec 5, 2023 | Pending |
Array
(
[id] => 18844441
[patent_doc_number] => 20230406845
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => NOVEL POTASSIUM CHANNEL INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/239348
[patent_app_country] => US
[patent_app_date] => 2023-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39399
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 270
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18239348
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/239348 | Potassium channel inhibitors | Aug 28, 2023 | Issued |
Array
(
[id] => 18808668
[patent_doc_number] => 20230383002
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLS
[patent_app_type] => utility
[patent_app_number] => 18/326826
[patent_app_country] => US
[patent_app_date] => 2023-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5192
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18326826
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/326826 | Humanized BCMA antibody and BCMA-CAR-T cells | May 30, 2023 | Issued |
Array
(
[id] => 18763998
[patent_doc_number] => 11814384
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-14
[patent_title] => Inhibtors of Raf kinases
[patent_app_type] => utility
[patent_app_number] => 18/164326
[patent_app_country] => US
[patent_app_date] => 2023-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 79879
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18164326
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/164326 | Inhibtors of Raf kinases | Feb 2, 2023 | Issued |
Array
(
[id] => 18709115
[patent_doc_number] => 20230331718
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => COMPOSITIONS FOR MODULATING SPLICING
[patent_app_type] => utility
[patent_app_number] => 18/162085
[patent_app_country] => US
[patent_app_date] => 2023-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30594
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18162085
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/162085 | COMPOSITIONS FOR MODULATING SPLICING | Jan 30, 2023 | Pending |
Array
(
[id] => 18709115
[patent_doc_number] => 20230331718
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => COMPOSITIONS FOR MODULATING SPLICING
[patent_app_type] => utility
[patent_app_number] => 18/162085
[patent_app_country] => US
[patent_app_date] => 2023-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30594
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18162085
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/162085 | COMPOSITIONS FOR MODULATING SPLICING | Jan 30, 2023 | Pending |
Array
(
[id] => 19059022
[patent_doc_number] => 11938217
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-26
[patent_title] => Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
[patent_app_type] => utility
[patent_app_number] => 18/098505
[patent_app_country] => US
[patent_app_date] => 2023-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5986
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18098505
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/098505 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | Jan 17, 2023 | Issued |
Array
(
[id] => 18374280
[patent_doc_number] => 20230149358
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT
[patent_app_type] => utility
[patent_app_number] => 18/071724
[patent_app_country] => US
[patent_app_date] => 2022-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47536
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18071724
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/071724 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | Nov 29, 2022 | Pending |
Array
(
[id] => 18793890
[patent_doc_number] => 11827642
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-28
[patent_title] => Compositions useful for treating disorders related to KIT
[patent_app_type] => utility
[patent_app_number] => 17/983747
[patent_app_country] => US
[patent_app_date] => 2022-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 24860
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17983747
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/983747 | Compositions useful for treating disorders related to KIT | Nov 8, 2022 | Issued |
Array
(
[id] => 18916698
[patent_doc_number] => 11878968
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-23
[patent_title] => Aryl compounds and pharmaceutical compositions that modulate IKZF2
[patent_app_type] => utility
[patent_app_number] => 18/052462
[patent_app_country] => US
[patent_app_date] => 2022-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30843
[patent_no_of_claims] => 40
[patent_no_of_ind_claims] => 18
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052462
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052462 | Aryl compounds and pharmaceutical compositions that modulate IKZF2 | Nov 2, 2022 | Issued |
Array
(
[id] => 18384471
[patent_doc_number] => 11655240
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-05-23
[patent_title] => Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
[patent_app_type] => utility
[patent_app_number] => 17/964389
[patent_app_country] => US
[patent_app_date] => 2022-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 7
[patent_no_of_words] => 18555
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17964389
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/964389 | Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases | Oct 11, 2022 | Issued |
Array
(
[id] => 18701291
[patent_doc_number] => 11787790
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-17
[patent_title] => Benzimidazole derivative having fluorine-containing substituent, preparation and application thereof
[patent_app_type] => utility
[patent_app_number] => 17/947260
[patent_app_country] => US
[patent_app_date] => 2022-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4218
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 241
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17947260
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/947260 | Benzimidazole derivative having fluorine-containing substituent, preparation and application thereof | Sep 18, 2022 | Issued |
Array
(
[id] => 18337202
[patent_doc_number] => 20230129151
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYELIN RELATED AND INFLAMMATION RELATED DISEASES OR DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/895280
[patent_app_country] => US
[patent_app_date] => 2022-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12236
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17895280
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/895280 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYELIN RELATED AND INFLAMMATION RELATED DISEASES OR DISORDERS | Aug 24, 2022 | Pending |
Array
(
[id] => 18451540
[patent_doc_number] => 20230192818
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => SARS-COV-2 ANTIBODIES AND RELATED COMPOSITIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/820536
[patent_app_country] => US
[patent_app_date] => 2022-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33144
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17820536
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/820536 | SARS-COV-2 ANTIBODIES AND RELATED COMPOSITIONS AND METHODS OF USE | Aug 16, 2022 | Abandoned |
Array
(
[id] => 18109437
[patent_doc_number] => 20230002317
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => NOVEL SMALL MOLECULE SHC BLOCKERS USED FOR TREATING LIVER DISEASE AND METABOLIC DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/809158
[patent_app_country] => US
[patent_app_date] => 2022-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28603
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17809158
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/809158 | Small molecule SHC blockers used for treating liver disease and metabolic disease | Jun 26, 2022 | Issued |
Array
(
[id] => 18159846
[patent_doc_number] => 20230026438
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => PROTEASE INHIBITORS AS ANTIVIRALS
[patent_app_type] => utility
[patent_app_number] => 17/830185
[patent_app_country] => US
[patent_app_date] => 2022-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58370
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17830185
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/830185 | Protease inhibitors as antivirals | May 31, 2022 | Issued |
Array
(
[id] => 18329187
[patent_doc_number] => 11634415
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-25
[patent_title] => Derivatives of substituted morpholines and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/824644
[patent_app_country] => US
[patent_app_date] => 2022-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8552
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17824644
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/824644 | Derivatives of substituted morpholines and uses thereof | May 24, 2022 | Issued |
Array
(
[id] => 18093060
[patent_doc_number] => 20220411401
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => COMPOUNDS FOR THE TREATMENT OF SARS
[patent_app_type] => utility
[patent_app_number] => 17/751659
[patent_app_country] => US
[patent_app_date] => 2022-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11930
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17751659
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/751659 | Compounds for the treatment of SARS | May 22, 2022 | Issued |
Array
(
[id] => 18057901
[patent_doc_number] => 20220388987
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => SUBSTITUTED HETEROCYCLIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/743615
[patent_app_country] => US
[patent_app_date] => 2022-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16087
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17743615
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/743615 | Substituted heterocyclic compounds | May 12, 2022 | Issued |
Array
(
[id] => 18226942
[patent_doc_number] => 20230065936
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 17/716518
[patent_app_country] => US
[patent_app_date] => 2022-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 68592
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17716518
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/716518 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Apr 7, 2022 | Abandoned |